Abstract
By means of non-targeted quantitative determination of various low-molecular-weight metabolites in biological samples, metabonomics enables a better understanding of the metabolic variation in organisms subject to internal and external stimuli. As a result, it is particularly suitable for characterizing the metabonomic alternation associated with diseases and exploring the disease-related early metabolic biomarker clusters, which may provide a novel approach to the early diagnosis of diseases and individual medication. Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease in which autoantibodies can cause tissue damage and potentially life-threatening mul-tiple organ failure. The complicated pathogenesis and varied clinical symptoms of SLE pose great challenges for the diagnosis and monitoring of this disease. Development of new biomarkers that can be used to reliably confirm SLE or monitor its progression is still one of the main goals and challenges in SLE research. Metabolomics are alternative biomarker discovery approaches. In order to explore the application of metabolomics in SLE, we summarize the current progress in the field of metabtomics in the studies of SLE. Key words: Lupus erythematosus, systemic; Metabolomics; Review
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
